narvo vexar
BioMarin Pharmaceutical (BMRN) has agreed to acquire rare disease drug developer Amicus Therapeutics (FOLD) in an all-cash transaction worth nearly $4.8B, the companies announced on Friday.
As part of the transaction, San Rafael, California-based BioMarin (BMRN) will offer $14.50 per
